Xinwei Medical releases 2025 annual performance: Shareholders' profit attributable to owners of the company is 83.335 million yuan

DoNews, March 26 news, Xinwei Medical-B (HK6609) announced its annual performance for the year ending December 31, 2025. The group achieved revenue of 408 million yuan (RMB, the same below), a year-on-year increase of 46.9%; gross profit of 290 million yuan, a year-on-year increase of 59.3%; research and development costs of 40.761 million yuan, a year-on-year decrease of 30.8%; and a profit attributable to shareholders of 83.335 million yuan, turning a profit from a loss compared to the previous year; basic earnings per share of 2.21 yuan.

In the fiscal year of 2025, the company achieved revenue of 408.3 million yuan, a year-on-year increase of 46.9%. The group reported a net profit attributable to shareholders of 83.335 million yuan, a significant turnaround from a net loss of approximately 13.6 million yuan in the previous year.

This transformation was primarily due to the rapid revenue growth in all three major business segments of ischemic stroke, hemorrhagic stroke, and interventional access, along with further improvements in the company’s operational efficiency.

In 2025, the company’s ischemic stroke business revenue grew by 31.8% year-on-year, mainly due to the wide clinical recognition of its differentiated competitive advantage in intracranial thrombectomy catheters, with large-bore aspiration and cascade aspiration technology (CATCH) included in the “Chinese Expert Consensus on Endovascular Treatment Techniques for Acute Ischemic Stroke 2025.” The product has been used in over 450 hospitals, leading to rapid revenue growth; (2) mature products saw significant sales growth after being included in centralized procurement.

In the hemorrhagic stroke business, the company has established a complete aneurysm treatment solution. The company’s intracranial stent (recognized as an innovative medical device by NMPA) entered approximately 500 hospitals in its first commercial year, driving a rapid increase in market share for embolization coils.

At the same time, the company’s flow-directed devices were approved for market launch by NMPA in 2025, facilitating clinical promotion and application. For the aforementioned reasons, the company’s hemorrhagic stroke business revenue grew by 223.2% year-on-year in 2025.

In the interventional access business, the company’s star product, vascular occluders, has been used in over 1,800 hospitals, with annual clinical usage exceeding 200,000 units, achieving over 100 million yuan in revenue for a single product in 2025. Meanwhile, the company is promoting the development and commercialization of the second-generation vascular occluders to continue expanding market share.

In 2025, the company’s overseas market revenue grew by 101.3% compared to 2024, primarily attributable to the rapid advancement of the company’s overseas product registration and promotion efforts. In the overseas market, the company’s thrombectomy stents, occlusion balloon catheters, distal access catheters, and microcatheters have obtained CE or FDA certification, and have acquired 56 registration certificates in 13 other countries or regions.

As of now, the company is also conducting over 130 product registration efforts in 29 other countries or regions, expanding sales channels and establishing a foundation for achieving long-term overseas sales goals.